- Omega Diagnostics says its FY results will be in line with market views, with revenues seen at £14.3m and adjusted profit before tax at £1.1m.

"We have reached a significant milestone in achieving design freeze with our VISITECT CD4 development programme," the company said.

"We remain confident in completing the verification and validation programme to deliver a unique product which we believe will meet a large unmet medical need for people living with HIV infections in resource-limited countries."

Omega said it had also been successful in achieving full operational capability with its manufacturing facility in Pune, India.

"Whilst we have already indicated we expect to achieve modest sales with our Malaria range of tests this year, we believe we have created a valuable asset which can grow shareholder value in the years ahead."

The company was further encouraged by the ongoing performance of its core business.

"Our Food Intolerance division continues to grow at a healthy rate and we are reviewing initiatives as to how we may grow this business in North America.

"Our allergy business in Germany achieved a 3% increase in euro denominated turnover, reversing a declining trend in recent years."

Story provided by